Class information for:
Level 1: ANDROGEN DEPRIVATION THERAPY//INTERMITTENT ANDROGEN SUPPRESSION//BICALUTAMIDE

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
1802 2409 32.3 70%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
157 21931 BENIGN PROSTATIC HYPERPLASIA//PROSTATE CANCER//PROSTATE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ANDROGEN DEPRIVATION THERAPY Author keyword 101 39% 9% 208
2 INTERMITTENT ANDROGEN SUPPRESSION Author keyword 94 94% 1% 33
3 BICALUTAMIDE Author keyword 59 44% 4% 102
4 DEGARELIX Author keyword 54 80% 1% 33
5 COMBINED ANDROGEN BLOCKADE Author keyword 53 69% 2% 45
6 ANDROGEN ANTAGONISTS Author keyword 40 48% 3% 61
7 INTERMITTENT ANDROGEN DEPRIVATION Author keyword 27 92% 0% 11
8 ANDROGEN DEPRIVATION Author keyword 24 26% 3% 81
9 INTERMITTENT HORMONE THERAPY Author keyword 24 91% 0% 10
10 FLUTAMIDE Author keyword 22 19% 4% 105

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 ANDROGEN DEPRIVATION THERAPY 101 39% 9% 208 Search ANDROGEN+DEPRIVATION+THERAPY Search ANDROGEN+DEPRIVATION+THERAPY
2 INTERMITTENT ANDROGEN SUPPRESSION 94 94% 1% 33 Search INTERMITTENT+ANDROGEN+SUPPRESSION Search INTERMITTENT+ANDROGEN+SUPPRESSION
3 BICALUTAMIDE 59 44% 4% 102 Search BICALUTAMIDE Search BICALUTAMIDE
4 DEGARELIX 54 80% 1% 33 Search DEGARELIX Search DEGARELIX
5 COMBINED ANDROGEN BLOCKADE 53 69% 2% 45 Search COMBINED+ANDROGEN+BLOCKADE Search COMBINED+ANDROGEN+BLOCKADE
6 ANDROGEN ANTAGONISTS 40 48% 3% 61 Search ANDROGEN+ANTAGONISTS Search ANDROGEN+ANTAGONISTS
7 INTERMITTENT ANDROGEN DEPRIVATION 27 92% 0% 11 Search INTERMITTENT+ANDROGEN+DEPRIVATION Search INTERMITTENT+ANDROGEN+DEPRIVATION
8 ANDROGEN DEPRIVATION 24 26% 3% 81 Search ANDROGEN+DEPRIVATION Search ANDROGEN+DEPRIVATION
9 INTERMITTENT HORMONE THERAPY 24 91% 0% 10 Search INTERMITTENT+HORMONE+THERAPY Search INTERMITTENT+HORMONE+THERAPY
10 FLUTAMIDE 22 19% 4% 105 Search FLUTAMIDE Search FLUTAMIDE

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 HORMONE AGONISTS 113 62% 5% 117
2 ORCHIECTOMY 99 37% 9% 212
3 FLUTAMIDE 99 32% 10% 252
4 BILATERAL ORCHIECTOMY 67 77% 2% 46
5 BICALUTAMIDE MONOTHERAPY 56 80% 1% 35
6 ANDROGEN DEPRIVATION THERAPY 50 17% 11% 272
7 NILUTAMIDE 48 71% 2% 39
8 INTERMITTENT ANDROGEN SUPPRESSION 41 58% 2% 48
9 NONSTEROIDAL ANTIANDROGEN 37 59% 2% 41
10 BICALUTAMIDE 150 MG 35 59% 2% 40

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them 2015 8 103 61%
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature 2010 86 43 93%
Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer A Meta-analysis of Randomized Trials 2011 99 31 42%
Androgen deprivation therapy for prostate cancer 2005 396 47 47%
Review of Major Adverse Effects of Androgen-deprivation Therapy in Men With Prostate Cancer 2009 93 45 78%
Treatment of Prostate Cancer With Intermittent Versus Continuous Androgen Deprivation: A Systematic Review of Randomized Trials 2013 23 23 78%
Combined androgen blockade for prostate cancer: Review of efficacy, safety and cost-effectiveness 2011 20 24 88%
Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis 2000 165 44 73%
Gonadotropin-releasing hormone: An update review of the antagonists versus agonists 2012 18 33 64%
Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis 2014 5 39 64%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 WARD 14 4 75% 0.1% 3
2 J ANESE UROL ASSOC 2 67% 0.1% 2
3 STRATEG INVEST COMPREHENS CANC NETWORK 2 27% 0.2% 6
4 INTEGRAT CANC THER Y UROL 2 11% 0.6% 15
5 FARMACOVIGILANCIA ASTURIAS 1 50% 0.1% 2
6 UROEVIDENCE 1 100% 0.1% 2
7 UROL R 1 50% 0.1% 2
8 PLYMOUTH ONCOL 1 33% 0.1% 3
9 GERIATR PROGRAM 1 10% 0.5% 11
10 MED GRP 74 1 40% 0.1% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000149344 ABIRATERONE//ENZALUTAMIDE//CASTRATION RESISTANT PROSTATE CANCER
2 0.0000148714 AZALINE B//ANTIOVULATORY ACTIVITY//LHRH ANTAGONISTS
3 0.0000129534 SELECTIVE ANDROGEN RECEPTOR MODULATOR//SARM//SARMS
4 0.0000085145 RECTAL TOXICITY//HYPOFRACTIONATION//LATE RECTAL TOXICITY
5 0.0000082086 FOSFESTROL//IDIOPATHIC URETHRITIS//5 ALPHA ANDROSTANEDIOL
6 0.0000069500 RADICAL PROSTATECTOMY//PROSTATECTOMY//SALVAGE RADIOTHERAPY
7 0.0000057017 LHRH RECEPTOR//AN 152//ENDOCRINE POLYPEPTIDE CANC
8 0.0000052996 PENILE REHABILITATION//CAVERNOUS NERVE//RADICAL PROSTATECTOMY
9 0.0000051261 SHIONOGI CARCINOMA 115//VITAMIN B 12B//CLIN EXPT PATHOPHYSIOL
10 0.0000050907 PELVIC LYMPH NODE DISSECTION//EXTENDED PELVIC LYMPH NODE DISSECTION//LYMPH NODE INVASION